4.6 Review Book Chapter

Control of Immunity by the TNFR-Related Molecule OX40 (CD134)

Journal

ANNUAL REVIEW OF IMMUNOLOGY, VOL 28
Volume 28, Issue -, Pages 57-78

Publisher

ANNUAL REVIEWS
DOI: 10.1146/annurev-immunol-030409-101243

Keywords

OX40L; costimulation; T cells; autoimmunity; infectious disease; vaccination

Categories

Funding

  1. NCI NIH HHS [CA91837, R01 CA091837, R01 CA091837-07] Funding Source: Medline
  2. NIAID NIH HHS [R56 AI067341, R01 AI067341, AI49453, U19 AI070535-040003, R01 AI067341-04, AI070535, R01 AI049453-08, U19 AI070535, R01 AI049453, AI67341] Funding Source: Medline
  3. NATIONAL CANCER INSTITUTE [R01CA091837] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI067341, R01AI067341, U19AI070535, R01AI049453] Funding Source: NIH RePORTER

Ask authors/readers for more resources

TNFR/TNF superfamily members can control diverse aspects of immune function. Research over the past 10 years has shown that one of the most important and prominent interactions in this family is that between OX40 (CD134) and its partner OX40L (CD252). These molecules strongly regulate conventional CD4 and CD8 T cells, and more recent data are highlighting their ability to modulate NKT cell and NK cell function as well as to mediate cross-talk with professional antigen-presenting cells and diverse cell types such as mast cells, smooth muscle cells, and endothelial cells. Additionally, OX40-OX40L interactions alter the differentiation and activity of regulatory T cells. Blocking OX40L has produced strong therapeutic effects in multiple animal models of autoimmune and inflammatory disease, and, in line with a prospective clinical future, reagents that stimulate OX40 signaling are showing promise as adjuvants for vaccination as well as for treatment of cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available